~," Meningiomas were removed from four patients and estradiol binding was measured in the tumor tissue. Cell cultures were established and an in vitro system was developed to test the biological activity of physiologically relevant concentrations (10 -7 M and 10 -9 M) of estradiol-17r progesterone, and the antiestrogen, tamoxifen, on the growth of meningioma cells in early culture (passages 3 to 5). Assays of the frozen surgical specimens demonstrated cytosolic estradiol binding, with levels of 0.3 to 26.7 femtomoles (fM)/mg protein, in all four tumors. Nuclear estradiol binding was detected in three tumors, with levels of 16.8 to 39.5 fM/mg protein. In cell culture, estradiol at either 10 -7 M or 10 -9 M consistently stimulated cell growth in all four cultures. When tested alone, progesterone stimulated the growth of all four tumors and tamoxifen stimulated the growth of three of the four tumors, but the levels of stimulation produced by either of these compounds were less pronounced than the level produced by estradiol. When tested in combination with estradiol, progesterone significantly inhibited the growth stimulation produced by estradiol in all four meningioma cultures and tamoxifen significantly inhibited estradiol-induced growth stimulation in three of four cultures. It is not known if these effects are mediated by a hormone receptor or by a hormone binder different from a true receptor, or if they are caused by alterations in cellular metabolism that are independent of specific hormone binding. However, the authors conclude that this in vitro technique can be used to further study the biological activity of hormones on human meningiomas in order to answer these questions.
M
ENINGIOMAS are tumors arising from the arachnoid cells covering the brain and spinal cord. Hormonal modulation of human meningiomas has been suggested to explain the following phenomena: meningiomas are three times more common in women than in men; TM they may enlarge in relation to pregnancy or the menstrual cycle; 2 and they occur more commonly in women with breast cancer than in a matched population of women without breast cancer. 22 Evidence for the presence of cytosolic estrogen and/or progesterone binding in some meningiomas has been presented by several investigators, but in most studies the number of tumors demonstrating specific binding is small and the level of estrogen binding is much lower than in breast cancer. 3-7' 11-13.17,21,25,26,28 In addition, a significant number of meningiomas have been noted to have high levels of cytosolic progesterone binding without having elevated levels of cytosolic estrogen binding, a situation not usually found in other hormonally responsive tissues, such as breast or uterus. 9.16,19 To date, the evidence that meningiomas contain putative sex steroid receptors rests entirely upon binding studies; there have been no studies of hormoneinduced receptor translocation or growth stimulation. Thus, there has been no direct evidence for the biological activity of any of the sex steroids on meningiomas. Therefore, we studied the ability of physiologically relevant concentrations of estradiol and progesterone, and similar concentrations of the anti-estrogen, tamoxifen, to modulate the growth of four human meningiomas in cell culture. Our findings are presented here.
Materials and Methods

Clinical Material
Tumor specimens were obtained from four patients. The first patient (Case 1) was a 66-year-old woman who had had a mastectomy 13 years previously for a breast cancer. Hormonal receptor assays had not been performed. She developed syncopal episodes and underwent removal of a left cerebellopontine angle syncytial meningioma. The second patient (Case 2) was a 64-year-old man who developed a grand mal seizure and underwent removal of a right frontal falx transitional meningioma. The third patient (Case 3) was a 60-yearold woman with a 1-month history of deteriorating memory and gait. She developed seizures, and underwent surgery for the removal of a bifrontal falx transitional meningioma. The last patient (Case 4) was a 60-year-old woman with a 3-month history of headache and right arm weakness who underwent removal of a right frontal fibroblastic meningioma.
Cell Culture Studies
Samples of meningioma tissue were obtained from unselected patients undergoing surgery for a meningioma. One portion of each meningioma was examined histologically. Another portion was immediately frozen at -20~ in a cryostat and then stored at -800C until binding studies were performed. A third portion of each tumor was placed in 90% F-10 medium* with 10% heat-inactivated (at 56~ for 30 minutes) fetal bovine serum (FBS) for transport to the tissue culture laboratory. These samples were cut into 1-mm fragments, explanted into 75-sq cm tissue culture flasks,t and maintained at 350C with two changes of medium per week. Of the 10 meningiomas, four (from Cases 1 to 4) showed sufficient growth under these conditions to allow further in vitro testing.
When the contents of these flasks became confluent (at approximately 4 to 6 weeks), the medium was removed; the cells were washed with Hanks' balanced salt solution without magnesium or calcium, and were incubated with trypsin (0.05%) EDTA (ethylenediaminetetra-acetic acid, 0.02%) for 10 minutes at 35"C. The resulting cell suspension was centrifuged for 15 minutes. The supernatant was decanted and the remaining cell pellet was resuspended in 1 ml of nutrient medium and passed into new culture flasks. This process was repeated until adequate numbers of cells were available for testing. The cells were dispersed in the usual manner, and they were then triturated with a No. 22 needle to achieve a single cell suspension. The cells were counted in a hemocytometer. Nutrient medium was added to give a final concentration of 5 • 103 cells/ml. To each well of several 96-well fiatbottom tissue culture plates~ was added either 50 ul or 100 ul of the cell suspension to give 250 or 500 cells/ well, respectively. The plates were incubated at 35"C in * F-10 medium obtained from Gibco Laboratories, Grand Isle, New York.
t Tissue culture flasks manufactured by Corning Glass Works, Corning, New York.
:~ Tissue culture plates manufactured by Coming Glass Works, Corning, New York. a 95:5 mixture of air and CO2 for 72 hours to allow adequate cell adherence. At this time, one plate from each meningioma was fixed with methanol, stained with 2% Giemsa, and the number of cells in each well was counted to obtain an estimate of the plating efficiency for each tumor. The set of plates containing a uniform distribution nearest 100 cells/well was chosen for the remaining studies. Steroid-stripped sera were prepared by mixing heat-inactivated FBS with 0.25% (w/v) Norite activated charcoalw for 16 hours at 25~ followed by ultracentrifugation (105 G at 4~ and passage through a 0.22-1zm filter.II Control solutions contained nutrient medium plus 10% stripped FBS. Estradiol-17~, progesterone, and tamoxifen free base were prepared in stock solutions of 95% ethanol. Appropriate amounts were added to sterile bottles, and the ethanol was evaporated with CO2. The F-10 medium with stripped FBS was added to produce 10 -7 M or 10 -9 M concentrations.
The medium was removed from the test plates and replaced with 100 ul of test medium or control medium. The typical 96-well plate had 24 control wells and 24 wells for each experimental condition. Solutions were arranged diagonally in order to minimize positional advantage and artifacts. 15 Media were changed daily. After 4 days the plates were fixed with methanol and stained with 2% Giemsa, and each well was microscopically counted. The diagonal pattern varied between plates so that the observer was unaware of the treatment administered to each well. Infected wells were excluded. The remaining cell counts for each test group were then statistically analyzed using both a Poisson test and a Wilcoxon test) '8'~~176 For each meningioma, data were obtained from four plates for each test of a single hormone versus control, for a maximum of 96-well counts per treatment, or from two plates for each test hormone combination versus a single hormone or versus control, for a maximum of 48 counts per combined treatment.
The mean number of cells per well was calculated for each test condition. In order to compare test conditions with each other and between tumors from individual patients, a growth index (GI) was calculated: 
Effect of sex steroids on meningioma cells in vitro Additional Studies
Preparation of cytosolic and nuclear fractions and the subsequent steroid-binding assays were performed as described previously.14
Results
Tumors from four patients had sufficient tissue and showed adequate growth in F-10 medium with 10% heat-inactivated FBS to allow in vitro testing to be performed at early passage under these conditions. Preliminary studies with slower-growing tumors and with longer incubation periods were hampered by larger numbers of contaminated wells, which obscured the cell counts. With the current technique of daily changes of medium during a 4-day incubation period, an average of six wells per 96-well plate became contaminated (range 0 to 10) ( Table 1 ) . Earlier studies had shown that cell concentrations of less than 250 cells/well were ideal for microscopic counting of the cell number. Larger cell numbers sometimes led to difficulty in distinguishing individual cells. Therefore, because plating efficiencies varied from 5.6% to 34.4%, the number of cells placed into each well had to be adjusted accordingly. Preliminary studies had shown that cell clumping was a barrier to achieving the single-cell suspension required for adequate testing. Thus, the low plating efficiencies of some tumors could be due to the degree of mechanical disruption required to overcome this problem.
Assays for cytosolic estradiol binding were performed on the frozen surgical specimens of all four of the meningiomas studied, and showed levels ranging from 0.3 to 26.7 fM/mg protein ( amount of specimen was available in Case 3 to study cytosolic progesterone binding as well, and a value of 8.5 fM/mg protein was detected.
As shown in Table 2 , estradiol at either 10 -7 M or 10 -9 M concentrations consistently stimulated cell growth in all four meningiomas relative to control wells. In tumors from Cases 1, 2, and 4, estradiol at 10 -7 M produced a higher GI than at 10 -9 M, while the tumor from Case 3 showed the opposite result. In cultures from Cases 1 and 3, tamoxifen stimulated cell growth at both concentrations (10 -v M and 10 -9 M), although to a lesser degree than estradiol at the equivalent concentration. In specimens from Case 2, tamoxifen stimulation was noted only at 10 -7 M. In Case 4 cultures, the Poisson and Wilcoxon tests differed on the level of significance of the possible tamoxifen-induced stimulation. At a 10 -7 M concentration of tamoxifen, the GI was 1.42, with a p value < 0.0001 by the Poisson test and < 0.02 by the Wilcoxon test. At 10 -9 M tamoxifen, the GI was 1.10, with a p value < 0.0001 by the Poisson test but > 0.2 by the Wilcoxon test.
The combination of estradiol and tamoxifen at either concentration (10 -7 M or 10 -9 M) was not statistically different from control wells for specimens from Case 1, whereas in samples from Cases 2, 3, and 4 the levels of significance varied between the two statistical tests. However, it is notable that for Cases 1, 2, and 3 the addition of tamoxifen to estradiol at equivalent concentrations significantly blocked the growth stimulation produced by estradiol ( Table 2) . For Case 4, the effect of tamoxifen on blocking the estradiol-induced growth stimulation was equivocal. At both concentrations, the Poisson test revealed the blocking effect to be statistically significant (p < 0.0001 at 10 -7 M and p < 0.0002 at 10 -9 M), whereas the Wilcoxon test did not show significance (p > 0.2 at 10 -7 M and p < 0.5 at 10 -9 M).
Progesterone stimulated cell growth but the effects were less pronounced and more variable than those produced by estradiol (Table 3 ). In cultures from Cases 2 and 3, progesterone stimulated cell growth to levels of significance by both statistical tests. In cultures from Cases 1 and 4, a 10 -7 M concentration of progesterone significantly stimulated cell growth by both tests while, at 10 -9 M, cell growth stimulation was much less pronounced and was associated with disagreement of the statistical tests. In both Cases 1 and 4, these levels were significant according to the Poisson test (p < 0.0001), while the Wilcoxon test suggested less statistical power (p < 0.02 for Case 1 and p < 0.06 for Case 4). The combination of estradiol and progesterone was generally not statistically different from controls by both tests, with the exception of cultures in Case 3 at l0 -9 M. However, as shown by the p values in parentheses in Table 3 , the addition of progesterone at l0 -7 M blocked the cell growth stimulation produced by estradiol (10 -7 M) in all four cultures. Both statistical tests were in agreement in all four instances that the combination of estradiol (10 -7 M) plus progesterone (10 -7 M) produced a GI significantly lower than that produced by estradiol (10 -7 M) alone. For Cases 1 and 2, the lower concentration (10 -9 M) of progesterone also inhibited the growth stimulation induced by estradiol (10 -9 M). However, for Cases 3 and 4, estradiol (10 -9 M) plus progesterone (10 -9 M) produced a lower GI than that of estradiol (10 -9 M) alone, but the results of the two statistical tests differed. In both instances, the Poisson test suggested a level of significance (p < 0.0001), while the Wilcoxon test indicated a p value of < 0.06 for Case 3 and < 0.02 for Case 4.
Discussion
Meningiomas are tumors arising from the arachnoid cells covering the brain and spinal cord. They are usually benign and are surgically curable in most cases. However, those located at the skull base and those that are invasive may not be amenable to complete surgical removal, and recurrence may necessitate multiple neurosurgical procedures. Until now, the only alternative Effect of sex steroids on meningiorna cells in vitro to surgery has been radiotherapy. 27 The possibility of medical treatment through hormone modulation has been suggested, and numerous studies have detected putative receptors for estrogen and progesterone within some meningiomas. 3-6,11-13.17.21,23,25.26,28 However, to date, all such studies have only reflected the ability of cytosolic or nuclear fractions of meningiomas to bind estrogen or progestin. No evidence has been reported to demonstrate biological activity of these steroid hormones on meningioma cells.
In this investigation, we have studied early-passage cultured cells from four human meningiomas. Longterm cultures or cloned or established cell lines were avoided since they may not be representative of the specimen in vivo. Primary cultures could not be used since they would not provide an adequate number of cells for evaluation; thus, the tumors were studied at passages 3 to 5. Although the tumors from four patients were not preselected for this study by any chemical or biochemical criteria, the four cultured specimens may, to some extent, show a certain element of in vitro selection. Because of the physical requirements of the assay system, the only meningiomas that could be used were those that demonstrated adequate growth in F-10 medium containing 10% heat-inactivated FBS. Since FBS may contain variable amounts of estrogen, progesterone, and other hormones, it is possible that during the initial growth period a preselection occurred for cells responding to these factors. Thus, it is recognized that the four tumors tested may represent a subset of all meningiomas. In this regard, it is notable that three of the meningiomas cultured were derived from surgical samples containing detectable levels either of nuclear estradiol binding (Cases 2 and 4) or of cytoplasmic and nuclear estradiol binding (Case 1) ( Table 1 ). In Case 3, nuclear estradiol binding was not measured and cytoplasmic binding was low. In a recent study of estradiol binding in surgical meningioma specimens, TM we found cytoplasmic binding of estradiol in 21 (66%) of 32 specimens; of these, six (19%) had levels above 10 fM/ mg protein. Nuclear binding of estradiol was noted in 11 (50%) of 22 cases, with five (23%) having levels in excess of 10 fM/mg protein. Thus, nuclear binding of estradiol greater than 10 fM/mg in all three specimens in which it was tested suggests the possibility of some degree of unexpected in vitro selection for such tumors.
Physiologically relevant concentrations (10 -9 M and 10 -7 M) of estradiol stimulated the growth of all four meningiomas (Tables 2 and 3 ). Both tamoxifen and progesterone also demonstrated cell stimulation, but to a lesser extent than estradiol. Of most interest is the finding that tamoxifen blocked the estradiol-induced cell growth in three of four cases. The only exception was Case 4, in which the Poisson test suggested blocking of estradiol by tamoxifen but the Wilcoxon test revealed disagreement (Table 2 ). Progesterone had a similar effect and blocked the estradiol-induced growth stimulation in all cases except at 10 -9 M in Case 4, where the Poisson and Wilcoxon tests again disagreed. Thus, we conclude that a subset of meningiomas which includes, and which may be limited to, those tumors that demonstrate estradiol binding, also shows estradiol-induced growth stimulation of the tumor cells in culture. Moreover, the growth stimulation induced by estradiol can be significantly blocked by either tamoxifen or progesterone in at least three of four cases.
Our current study does not address the question of whether these effects on meningioma cell growth are mediated by a classical estrogen receptor. Arguing against this being a true receptor are the relatively low levels of cytoplasmic estradiol binding in the tumors in Cases 2, 3, and 4 (Table 1 ) and the studies by Schwartz, et al., 23 which suggest that the hormone binder in meningiomas can be partially displaced by compounds other than the hormone being tested. Thus, while the changes in cell growth that we have documented may be due to a hormone receptor, it is also possible that they are due to binding of the hormone or anti-hormone to a molecule other than a classical receptor. However, some work has suggested that, in addition to acting via the estrogen receptor, anti-estrogens may act via high-affinity anti-estrogen binding sites that are distinct from the estrogen receptor. 24 Therefore, the ultimate question for the clinician to decide will be whether estrogen, progesterone, tamoxifen, and related compounds alter meningioma growth, irrespective of whether this alteration is due to a classical receptor or to a different hormone binder. We hope that the demonstration of an in vitro system for testing the modulation of meningioma cells by sex steroids will allow this question to be answered and will provide a model for other investigations.
Future studies should explore the possibility that those patients with both breast cancer and meningioma (as in Case 1) may have a common cellular derangement associated with abnormal hormonal regulation of cell growth and tumor formation at these sites. Such studies should also consider the finding that the preponderance of human meningiomas in females may be related to an absence of chromosome 22; 29 thus, it would be useful to correlate levels of hormone binding and in vitro growth modulation with metaphase or prophase chromosomal banding of meningiomas. Finally, the techniques we have reported might profitably be altered so as to allow growth and testing of the larger group of meningiomas that show elevated progesterone binding but little or no estradiol binding. In this way the possibility that some meningiomas may differ in their responses to hormones or blocking agents might be explored.
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